We showed that the distribution of 89Zr-labeled PSMA-617 and PSMA-I&T could be monitored with PET imaging and determined the potential of 89Zr-labeled PSMA ligands to predict the tumor and normal tissue dose of their 177Lu-labeled counterpart using the biodistribution data. This evidence concerns the gene FOLH1 and neoplasm.